VanEck Gold Miners ETF vs uniQure N.V. Ordinary Shares — how do they compare? VanEck Gold Miners ETF trades at $85.12 (market cap $26.33B), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.48B). The key difference: VanEck Gold Miners ETF is far larger — about 17.8× uniQure N.V. Ordinary Shares's market cap, and VanEck Gold Miners ETF is trading nearer its 52-week high, uniQure N.V. Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Gold Miners ETF for 77 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| GDX | QURE | |
|---|---|---|
Market Cap | $26.33B | $1.48B |
Volume | 15,141,546 | 2,488,780 |
52-Week High | $115.84 | $70.59 |
52-Week Low | $68.28 | $9.03 |
Typical Hold Time | 77 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $728.62M |
Signals from Pluang's Aura AI — not financial advice
GDX trades at $87.24, down 1.46% on the day, with technical indicators showing a neutral to bearish bias amid mixed signals from moving averages and oscillators. The ETF's fundamental metrics are not provided in the snapshot, but recent news highlights ongoing institutional repositioning and comparisons between gold miners and physical gold. Support and resistance levels are tightly clustered around the current price, suggesting near-term consolidation.
The outlook for GDX hinges on gold price trends and interest rate movements, with potential upside from inflation hedging demand but risks from institutional selling and metal volatility. Investors face a balanced risk-reward scenario given neutral sentiment and lack of clear directional catalysts.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.
Read more on GDX →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →